JO
SLS icon

John Overdeck’s SELLAS Life Sciences SLS Stock Holding History

John Overdeck’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-403,165
Closed -$1.71M – 5396
2026
Q1 		$1.71M Sell
403,165
-679,042
-63% -$3.04M ﹤0.01% 2879
2025
Q4 		$4.08M Buy
1,082,207
+936,351
+642% +$1.82M 0.01% 1897
2025
Q3 		$235K Sell
145,856
-51,786
-26% -$92.2K ﹤0.01% 3319
2025
Q2 		$433K Buy
197,642
+149,355
+309% +$229K ﹤0.01% 2648
2025
Q1 		$52.1K Buy
+48,287
New +$57.3K ﹤0.01% 3041
2024
Q4 		– Sell
-16,591
Closed -$20.7K – 3453
2024
Q3 		$20.7K Buy
+16,591
New +$20.3K ﹤0.01% 3020
2022
Q4 		– Sell
-53,685
Closed -$108K – 3053
2022
Q3 		$108K Buy
53,685
+32,191
+150% +$88.9K ﹤0.01% 2220
2022
Q2 		$48K Buy
+21,494
New +$63K ﹤0.01% 2351

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.31% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

John Overdeck's SLS Position: Q2 2026 in Review

John Overdeck sold out of SELLAS Life Sciences (SLS) in Q2 2026, closing a stake of 403,165 shares — an estimated $1.71M sold.

John Overdeck first reported a position in SLS in Q2 2022 and held it in 8 quarters. The position peaked at $4.08M in Q4 2025. 190 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • John Overdeck reported no remaining SELLAS Life Sciences position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 403,165 SELLAS Life Sciences shares in Q2 2026, an estimated $1.71M.
  • John Overdeck first reported a position in SELLAS Life Sciences in Q2 2022 and held it in 8 quarters.
  • John Overdeck's SELLAS Life Sciences position peaked at $4.08M in Q4 2025.
  • 190 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.